Dr. Reddy's Laboratories launches Over-The-Counter Diclofenac Sodium Topical Gel 1% in US

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. market.

"The launch of Dr. Reddy's Diclofenac Sodium Topical Gel, 1% (OTC), is an important addition to our Pain / Analgesics portfolio of OTC products, and represents our continued commitment to the Private Label OTC space," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories. "We are pleased to partner with Encube Ethicals to bring this product to market for the benefit of consumers."

Dr. Reddy's Diclofenac Sodium Topical Gel, 1% (OTC), is used for the temporary relief of arthritis pain ONLY in the following areas:

- hand, wrist, elbow (upper body areas)
- foot, ankle, knee (lower body areas)

Voltaren® Arthritis Pain brand had total U.S. retail sales of approximately $44 million since launch in May 2020 according to IRI*.

Dr. Reddy's Diclofenac Sodium Topical Gel, 1% (OTC), will soon be available in multiple pack sizes to allow consumers a variety of purchasing options.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4336.2 as compared to the previous close of Rs. 4422.25. The total number of shares traded during the day was 36823 in over 4201 trades.

The stock hit an intraday high of Rs. 4481 and intraday low of 4330.05. The net turnover during the day was Rs. 162261608.

Voltaren® is a trademark of Novartis Corporation.

*IRI POS TOTAL US - MULO Period ending August 9, 2020

Source : Equity Bulls

Keywords